Press Releases Hua Medicine (Shanghai) Ltd.

Equities

2552

KYG4644K1022

Market Closed - Hong Kong S.E. Other stock markets 09:08:07 09/05/2024 BST			5-day change	1st Jan Change
1.57 ^HKD	+0.64%		-2.48%	-20.30%

03-28	Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hua Medicine Announces 2023 Interim Results	25/08/23	AQ
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China	10/10/22	AQ
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022	07/06/22	AQ
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine	13/05/22	AQ
Hua Medicine Announces 2021 Annual Results	17/03/22	AQ
Hua Medicine Shanghai : Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin	26/09/21	AQ
Hua Medicine Shanghai : and Sinopharm Announced Supply Chain Strategic Cooperation	15/09/21	AQ
Hua Medicine : Announces 2020 Interim Results	19/08/21	AQ
Hua Medicine : Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally	23/04/21	AQ
Hua Medicine Shanghai : VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR DORZAGLIATIN ACCEPTED IN CHINA BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION	23/04/21	PU
Hua Medicine Shanghai : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, JUNE 29, 2021	22/04/21	PU
Hua Medicine Shanghai : (I) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (II) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES; (III) PROPOSED RE-APPOINTMENT OF AUDITOR; AND (IV) NOTICE OF ANNUAL GENERAL MEETING	22/04/21	PU
Hua Medicine Shanghai : Environment, Social and Governance Report 2020	22/04/21	PU
Hua Medicine Shanghai : GRANT OF SHARE OPTIONS	22/03/21	PU
Hua Medicine Shanghai : Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission	19/03/21	AQ
Hua Medicine Shanghai : ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020	19/03/21	PU
Hua Medicine : Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial	18/12/20	AQ
Hua Medicine : Announces the Drug Manufacturing Permit Granted for Dorzagliatin	14/10/20	AQ
Hua Medicine Shanghai : Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China	17/08/20	AQ
Hua Medicine Shanghai : BUSINESS UPDATE ON COMMERCIALIZATION AGREEMENT AND STRATEGIC PARTNERSHIP FOR INVESTIGATIONAL FIRST-IN-CLASS NOVEL DIABETES TREATMENT DORZAGLIATIN WITH BAYER IN CHINA ANNOUNCEMENT OF POTENTIAL INSIDE INFORMATION	17/08/20	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Hua Medicine (Shanghai) Ltd.

Equities

2552

KYG4644K1022

Press Releases

Filters